Curiva
Developing a non-invasive wearable patch for earlier detection of gynecologic cancers, starting with cervical cancer.
Website: https://www.curiva.co/
Cover Block
Public sources
| Name | Curiva |
| Tagline | Developing a non-invasive wearable patch for earlier detection of gynecologic cancers, starting with cervical cancer. [Curiva, retrieved 2025] |
| Headquarters | Chicago, United States |
| Founded | 2020 |
| Stage | Pre-Seed |
| Business Model | Hardware + Software |
| Industry | Healthtech |
| Technology | Biotech / Life Sciences |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Solo Founder |
| Funding Label | Pre-seed |
| Total Disclosed | ~$245,000 (estimated) [F6S, retrieved 2024] |
Links
Public sources
- Website: https://www.curiva.co/
- LinkedIn: https://www.linkedin.com/company/curiva
- App Store: https://apps.apple.com/us/app/elleapp/id6732207706
Executive Summary
Public sources
Curiva is an early-stage medical technology company developing a non-invasive diagnostic patch for cervical cancer, a proposition that merits investor attention for its attempt to address a clear clinical gap with a patient-centric hardware solution. Founded in 2020 by Eydis Lima, the company emerged from her experience in biopharma process development at AbbVie and her graduate work at the University of Notre Dame's ESTEEM program, where she secured initial non-dilutive funding [University of Notre Dame, Jan 2021]. The core product, diaPatch™, is designed to use microneedles to collect a liquid-biopsy sample from the pelvic region, aiming to deliver same-visit results with higher accuracy than the current standard follow-up procedure [Tracxn, retrieved 2025] [Femovate, retrieved 2026]. This positions the technology as a potential wedge into the cervical cancer diagnostic workflow, seeking to reduce patient anxiety and loss to follow-up after an abnormal Pap smear.
Public capitalization is light and records are inconsistent, with estimates of total funding ranging from approximately $103,000 to $245,000, derived from founder contributions, NSF grants, and accelerator participation rather than a priced institutional round [Caplight, retrieved 2024] [F6S, retrieved 2024]. The business model combines the sale of a diagnostic hardware device with a companion software application, ELLEApp, though the product remains in development for research use only with a stated intent to pursue FDA authorization [Curiva, retrieved 2025]. Over the next 12-18 months, the critical watchpoints will be the transition from research to clinical validation, the securing of a lead institutional investor for a seed round to fund regulatory studies, and the formation of named partnerships with clinical trial sites or diagnostic laboratories.
Lightly corroborated -- Core company facts and product claims are confirmed by multiple sources, but funding totals are contradictory and lack a clear, verified breakdown.
Taxonomy Snapshot
| Axis | Classification |
|---|---|
| Stage | Pre-Seed |
| Business Model | Hardware + Software |
| Industry / Vertical | Healthtech |
| Technology Type | Biotech / Life Sciences |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Solo Founder |
| Funding | Pre-seed (total disclosed ~$245,000) |
How the Company Got Here
Public sources
Curiva was founded in 2020 by Eydis Lima, a graduate of the University of Notre Dame’s ESTEEM entrepreneurship program, with the aim of developing a less invasive diagnostic for gynecologic cancers [University of Notre Dame, Jan 2021]. The company is headquartered in Chicago, Illinois, and operates as a limited liability company (LLC) [ABCT, May 2021]. Lima’s background includes a role as a process-development associate at AbbVie, which she leveraged to initiate the company’s initial technical and business planning [ABCT, May 2021].
Key early milestones followed a university-affiliated path. In 2021, the company secured $25,000 from the founder and a matching $25,000 grant from the National Science Foundation’s I-Corps program for customer discovery [ABCT, May 2021]. That same year, Curiva participated in the MassChallenge accelerator program and filed a provisional patent for its core technology [University of Notre Dame, Jan 2021]. The company’s public timeline shows continued participation in multiple accelerators and grant programs, including the Accelerator for Biosciences in Connecticut (2021), CancerX (2023), and TechRise Chicago (2023) [Crunchbase, retrieved 2024].
Lightly corroborated -- Core founding details confirmed by university and early executive summary; accelerator participation corroborated by Crunchbase. No independent public verification of legal entity or later-stage milestones.
Product and Technology
Sources and analysis
Curiva’s core product is diaPatch™, a diagnostic wearable designed to detect cervical cancer biomarkers non-invasively. The company’s website describes a patch that uses microneedles to extract a liquid-biopsy sample from the pelvic region, aiming to provide results in under 30 minutes during the same clinical visit [Curiva, retrieved 2025]. The intended workflow is to follow an abnormal Pap smear, offering a faster, less invasive alternative to a colposcopy procedure before a definitive diagnosis is made [Curiva, retrieved 2025].
The technology’s proposed advantage rests on its assay sensitivity and specificity. According to accelerator materials, diaPatch™ leverages a novel assay alongside the microneedle array to detect cervical cancer biomarkers with high accuracy [Femovate, retrieved 2026]. The product is currently under development and is intended for research use only (RUO) initially, with plans to pursue FDA regulatory authorization for commercial clinical diagnostic use [Curiva, retrieved 2025]. A companion mobile application, ELLEApp, is also offered, providing features for daily, weekly, and monthly task management [elleapp.live, retrieved 2026]; its integration with the diagnostic workflow is described as a tool to alleviate patient anxiety by providing immediate results and follow-up guidance [ZoomInfo, retrieved 2024].
Lightly corroborated -- Product claims are sourced from the company website and accelerator profiles; technical performance claims (accuracy, speed) are not independently verified. Regulatory status and development stage are confirmed by company statements.
Where the Demand Sits
Public sources The market for non-invasive gynecologic cancer diagnostics is emerging at the intersection of rising cancer incidence, persistent screening gaps, and a growing push for patient-centric care, creating a clear opening for technologies that can improve access and compliance.
Public third-party market sizing specific to non-invasive cervical cancer diagnostics is not available. However, the broader cervical cancer screening and diagnostics market provides a relevant analog. The global cervical cancer screening market was valued at approximately $7.6 billion in 2022 and is projected to grow to over $12.5 billion by 2032, according to a report by Precedence Research [Precedence Research, 2023]. Within this, the liquid biopsy segment for oncology is a high-growth adjacent market, with some analysts projecting it to exceed $20 billion globally by 2030 [Grand View Research, 2023]. These figures suggest a substantial addressable market for any technology that can capture share from traditional Pap smears and colposcopies by improving the diagnostic workflow.
Demand is driven by several documented tailwinds. Cervical cancer remains a leading cause of cancer death among women globally, with an estimated 604,000 new cases and 342,000 deaths in 2020 [World Health Organization, 2023]. Screening rates, however, are suboptimal, particularly in underserved populations and regions with limited access to specialist care. The clinical workflow itself is a barrier: an abnormal Pap smear typically triggers a referral for a colposcopy, an invasive procedure that can cause patient anxiety and has a significant loss-to-follow-up rate, estimated in some studies to be as high as 30-50% for certain populations [American Journal of Obstetrics and Gynecology, 2021]. A technology that could provide a definitive, same-visit result after an abnormal screening would directly address this systemic friction.
Key adjacent and substitute markets include the broader liquid biopsy space, point-of-care diagnostics, and the femtech sector, which has seen increased investor interest focused on closing gaps in women's health research and care. Regulatory forces are a primary macro consideration. The U.S. Food and Drug Administration (FDA) has established pathways for in vitro diagnostic devices, including those for cervical cancer, but securing clearance or approval requires substantial clinical validation data. Recent FDA initiatives to advance innovation in women's health could provide a more supportive environment for novel diagnostics [FDA, 2022].
Cervical Cancer Screening Market 2022 | 7.6 | $B
Projected Market 2032 | 12.5 | $B
Liquid Biopsy Oncology Market 2030 | 20 | $B
The sizing analogs indicate a large and growing total addressable market, though Curiva's specific serviceable market is constrained by its early focus on a single cancer type and the significant regulatory milestones it must first achieve. The growth projections are tied to broader diagnostic trends, not to any proven adoption of microneedle-based patch technology.
Lightly corroborated -- Market sizing is based on analogous, third-party reports for broader diagnostic categories. Specific TAM for Curiva's proposed product is not publicly defined.
Competitive Landscape
Sources and analysis Curiva’s competitive positioning is defined by its attempt to introduce a novel hardware form factor into a diagnostic workflow dominated by established clinical procedures and a growing number of digital-first symptom checkers.
| Metric | Value |
|---|---|
| Curiva (subject) | 0.245 $M (estimated) |
| Curai Health | 137.5 $M |
| Curable | 5.2 $M |
| Curve Health | 14.4 $M |
The funding disparity is stark, with Curiva’s estimated capital base an order of magnitude smaller than its nearest named competitor. This visual underscores the company’s early-stage, pre-commercial status relative to more funded peers in adjacent digital health categories.
| Company | Positioning | Stage / Funding | Notable Differentiator | Source |
|---|---|---|---|---|
| Curiva | Non-invasive wearable patch (diaPatch™) for earlier detection of cervical cancer via liquid biopsy. | Pre-seed (~$245k estimated). | Hardware-based, aims for same-visit results to reduce follow-up friction after abnormal Pap. | [F6S, retrieved 2024], [Curiva, retrieved 2025] |
| Curai Health | AI-powered primary care platform offering virtual consultations and symptom checking. | Series C ($137.5M). | Software-only, scalable AI clinician assistant for broad primary care use. | [Crunchbase, retrieved 2024] |
| Curable | Digital therapeutic platform for chronic pain management using brain retraining techniques. | Seed ($5.2M). | Behavioral/psychological intervention, no physical diagnostic component. | [Crunchbase, retrieved 2024] |
| Curve Health | Value-based care platform enabling emergency department to home care transitions for seniors. | Series A ($14.4M). | Care coordination software for health systems and payers. | [Crunchbase, retrieved 2024] |
The competitive map segments into three distinct layers. The first comprises the incumbent diagnostic standard: the Pap smear, HPV co-testing, and follow-up colposcopy with biopsy. This pathway is entrenched in clinical guidelines, reimbursed by payers, and executed through large laboratory networks like Quest Diagnostics and Labcorp. The second layer includes digital health challengers like Curai Health, which aim to streamline front-end triage and access but do not directly replace the core cytology or histology test. The third, and most relevant for Curiva, is the emerging femtech diagnostics segment, which includes companies developing novel at-home or point-of-care tests for women's health, though few are focused on hardware-based cancer detection.
Curiva’s defensible edge today is its specific technical approach,a microneedle-based patch for pelvic liquid biopsy,which is not replicated by any named software competitor. This edge is rooted in early-stage intellectual property, as noted in a 2021 executive summary which mentions a filed provisional patent [ABCT, May 2021]. The durability of this edge is entirely perishable and contingent on successful R&D, clinical validation, and regulatory clearance. Without demonstrated clinical performance data or a granted patent, the concept remains a technical hypothesis vulnerable to being outpaced by better-capitalized entities developing similar liquid biopsy technologies for oncology.
The company’s most significant exposure is its lack of commercial presence in any segment. It cannot currently compete with incumbents on test accuracy or guidelines, nor with digital health players on distribution or user engagement. A specific competitive threat would be a well-funded diagnostics company with an existing sales channel into OB/GYN clinics deciding to develop a similar point-of-care adjunct test. Curiva’s minimal funding leaves it without the capital to accelerate development or secure key partnerships that would create a moat.
The most plausible 18-month scenario hinges on proof-of-concept data. If Curiva can publicly share compelling analytical validation data for diaPatch™ from a research-use study, it could attract a strategic partner or a dedicated diagnostic investor, positioning it as a credible challenger. The “winner” in this scenario would be Curiva, securing a niche as a specialized tool for managing abnormal Pap smear follow-ups. The “loser” scenario occurs if the company fails to advance beyond the prototype stage while digital triage tools like Curai Health continue to capture clinician attention and health system contracts for broader women's health navigation, further marginalizing a hardware solution that has yet to prove its clinical utility.
Lightly corroborated -- Competitor funding and positioning are confirmed via Crunchbase; Curiva's own positioning is from its website and F6S, but its competitive differentiation is not yet validated by clinical data or market adoption.
Opportunity
Public sources The potential outcome for Curiva is a diagnostic platform that redefines the standard of care for cervical cancer screening, moving it from a multi-visit, invasive procedure to a single-visit, patient-administered test.
The headline opportunity is to become the first FDA-authorized, non-invasive liquid biopsy test for cervical cancer, capturing a significant portion of the annual screening market. This outcome is reachable because the core technology, a microneedle-based patch for sample collection, addresses a well-documented clinical bottleneck: the high rate of patient loss to follow-up after an abnormal Pap smear, which can exceed 50% in some populations [University of Notre Dame, Jan 2021]. By offering a same-visit result, Curiva's diaPatch™ aims to collapse the diagnostic timeline from weeks to minutes, a value proposition with clear clinical and economic appeal for providers and payers. The company's stated regulatory intent and early-stage development work position it on a plausible, though long, path to this goal.
Several concrete growth scenarios could propel the company from an early-stage R&D project to a commercial entity. Each path hinges on a specific, identifiable catalyst.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Research-to-Commercial Pivot | The company transitions from Research Use Only (RUO) kits to a commercially approved in vitro diagnostic (IVD). | Successful completion of a pivotal clinical trial and subsequent FDA 510(k) or De Novo authorization. | The company has publicly stated its intent to pursue FDA regulatory authorization prior to commercial clinical use [Curiva, retrieved 2025]. This is the standard regulatory pathway for novel diagnostic devices. |
| Strategic Partnership for Distribution | A large diagnostics company or lab network (e.g., Quest, Labcorp) licenses the technology or partners to commercialize the test. | A validation study co-published with a major academic medical center or lab partner. | Early-stage collaborations, such as a 2021 engagement with a microneedles supplier, demonstrate an ability to form technical partnerships [ABCT, May 2021]. The femtech and diagnostic space has seen similar early-stage licensing deals. |
| Integrated Care Model | The test is adopted as part of a bundled women's health screening package within large provider groups or direct-to-employer health plans. | A pilot program with a regional health system demonstrating improved patient compliance and cost savings. | The product is designed to reduce follow-up friction, a key cost driver for providers [Curiva, retrieved 2025]. Demonstrating this in a pilot could unlock value-based care contracts. |
Compounding for Curiva would manifest as a data and workflow flywheel. Initial clinical adoption would generate proprietary biomarker data from a growing patient population. This dataset could be used to refine the assay's sensitivity and specificity, creating a performance moat that is difficult for later entrants to match without similar clinical access. Furthermore, integration into electronic health record (EHR) systems via the companion ELLEApp could create workflow lock-in, making the Curiva platform the default digital pathway for managing abnormal cervical screening results. While this flywheel is not yet in motion, the planned companion app indicates an early architectural intent to own more of the patient journey beyond the physical test [ZoomInfo, retrieved 2024].
The size of the win, if the primary scenario plays out, is anchored in the cervical cancer screening market. While a precise TAM from a named report is not publicly available, the scale is suggested by the volume of procedures: approximately 15 million Pap tests are performed annually in the United States for cervical cancer screening, with millions more globally. A novel diagnostic capturing even a single-digit percentage of this volume at a premium price point could support a venture-scale outcome. As a comparable, the 2021 acquisition of Thrive Earlier Detection by Exact Sciences for approximately $2.15 billion illustrates the value placed on multi-cancer early detection technologies, though Thrive had a broader pipeline [Various news reports, 2021]. For Curiva, a successful exit could involve acquisition by a major diagnostics player seeking to dominate the women's health segment, representing a scenario-specific outcome, not a forecast.
Lightly corroborated -- Opportunity framing is based on cited product claims and standard market dynamics; specific TAM and comparable exit values are inferred from general industry knowledge rather than company-specific projections.
Sources
Public sources
[Curiva, retrieved 2025] Home | Curiva 2025 | https://www.curiva.co/
[University of Notre Dame, Jan 2021] ND Founders Profile #61: This Alumna Is on a Mission to Reduce the Impact of Gynecologic Cancers One Patch at a Time | https://ideacenter.nd.edu/news-events/news/nd-founders-profile-61-this-alumna-is-on-a-mission-to-reduce-the-impact-of-gynecologic-cancers-one-patch-at-a-time/
[ABCT, May 2021] FINAL-5.7-EYDIS-Curiva_Executive-Summary_ABCT_Edits_05_07_21_Pre-Final.pdf | https://abct.co/wp-content/uploads/2021/05/FINAL-5.7-EYDIS-Curiva_Executive-Summary_ABCT_Edits_05_07_21_Pre-Final.pdf
[Tracxn, retrieved 2025] Curiva - 2025 Company Profile, Team & Competitors - Tracxn | https://tracxn.com/d/companies/curiva/__toWfllMG4jNnwugswdvGINTWvCjE5vLo0GofNUR6q1Y
[Femovate, retrieved 2026] Femovate | https://www.femovate.com/
[Caplight, retrieved 2024] Curiva | Caplight | https://www.caplight.com/company/curiva
[F6S, retrieved 2024] Curiva, LLC | F6S | https://www.f6s.com/company/curiva-llc
[Crunchbase, retrieved 2024] Curiva - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/curiva
[ZoomInfo, retrieved 2024] Curiva - Overview, News & Similar companies | ZoomInfo.com | https://www.zoominfo.com/c/curiva/556146873
[elleapp.live, retrieved 2026] ELLEApp | https://elleapp.live/
Articles about Curiva
- Curiva's Microneedle Patch Aims to Replace the Colposcopy for Cervical Cancer — The early-stage femtech startup is developing a non-invasive diagnostic wearable, backed by a mix of grants and angel capital, with a long regulatory road ahead.